VETOQUINOL Corporate brochure 2010 (year 2009)

ACTIVITY REPORT 2009 07 A STEADY FRAME OF MIND Now a key player in the animal health field with over 250 million euros revenues and a range of 700 brands, Vétoquinol currently generates nearly 80% of its turnover outside France and employs 1,550 people. However, its original mindset remains unchanged – that of an independent family-owned company, which has close ties to the practising veterinary community and is guided by a passion for innovation. ■ JANUARY THE ACQUISITION OF WOCKHARDT LTD IN INDIA TAKES SHAPE Wockhardt Ltd, the 6 th largest animal health company in India with a 5% market share, was seeking a market leading partner. Among the international laboratories who were interested, Vétoquinol proved to be the most energetic. An initial Memorandum of Understanding was signed in June and the final acquisition of the company, which is based in Mumbai (Bombay), took place in August. OUTSTANDING EVENTS 2001 • Acquisition of the Swiss Chassot Group • Launch of Aurizon ® , for the treatment of canine otitis 2003 • Launch of Propalin ® (treatment of incontinence in female dogs) • New R & D Centre in France: doubling of the surface area 2005 Launch of Clavaseptin ® (antibiotic) 2007 • Foundation of Vétoquinol Unipessoal Lda (Portugal) • Launch of Alfaxan ® (anaesthetic) 2002 • Acquisition of the Evsco and Tomlyn ranges (United States) • Launch of Prilium ® (canine cardiology) 2004 Opening of a marketing office in Shanghaï, China 2006 • Acquisition of Semyung Vet (Korea) and Vet Solutions (United States) • Listing of the shares on the Paris Stock Exchange 2008 • Acquisition of Ascor Chimici (Italy) and Viavet (Scandinavia) • Creation of a development unit in Canada • Launch of Vetprofen ® (anti-inflammatory) and Rubénal ® (nephrology) 2009 • Acquisition of the Animal Health Division of Wockhardt Ltd in India. • Launch of the “3D” Areas of Expertise advertising campaign TEAM SPIRIT OPEN-MINDEDNESS COMMITMENT PERFORMANCE GENUINENESS